FDA’s “Limited-Use” Approval Pathway Moves Forward Without Congressional Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency seeks input on which diseases, beyond drug-resistant infections, could benefit from rapid approval of therapies for subpopulations of patients; public hearing in February will ask how labeling should best express the limited indications.
You may also be interested in...
The Regulatory Pendulum Swings In Favor Of Antibiotics, But Will Investments Follow?
New incentives under the US government’s GAIN Act and FDA’s openness to faster development are helping put antibiotics back on investors’ radar screens, if not yet loosening their checkbooks.
Antibiotic Incentives: FDA’s Woodcock Says LPAD Could Be Better Than Exclusivity, But Questions Remain
Rep. Phil Gingrey, lead sponsor of the Generating Antibiotic Incentives Now Act, says industry still has questions about the proposed approval pathway for antibiotics treating life-threatening diseases, further clouding its prospects.
FDA Exploring Limited-Use Approvals For Antibiotics Based On Small Development Programs
The agency would like to have a “special medical use” category for drugs, such as antibiotics for bacteria resistant to current therapies, that could be approved based on small trials and whose labeling says they should not be prescribed off-label.